Abuse resistant lysine amphetamine compounds
DC CAFCFirst Claim
1. A pharmaceutical composition comprising an unprotected prodrug and one or more pharmaceutically acceptable additives;
- wherein said prodrug consists of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof;
wherein said composition is in a form suitable for oral administration;
wherein said composition provides release of amphetamine as an active from said prodrug following oral administration; and
wherein said prodrug has limited bioavailability of amphetamine when administered through alternative routes of administration.
5 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
-
Citations
18 Claims
-
1. A pharmaceutical composition comprising an unprotected prodrug and one or more pharmaceutically acceptable additives;
-
wherein said prodrug consists of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof; wherein said composition is in a form suitable for oral administration; wherein said composition provides release of amphetamine as an active from said prodrug following oral administration; and wherein said prodrug has limited bioavailability of amphetamine when administered through alternative routes of administration. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
- 15. A pharmaceutical composition comprising an oral dosage form of an unprotected prodrug consisting of L-lysine-d-amphetamine or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable additives.
-
18. An oral pharmaceutical dosage form for the administration of amphetamine comprising an unprotected prodrug and one or more pharmaceutically acceptable additives;
-
wherein said prodrug consists of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof; wherein said composition provides limited release of amphetamine as an active from said prodrug following oral administration; and wherein said prodrug has limited bioavailability of amphetamine when administered through alternative routes of administration.
-
Specification